{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:41:16Z","timestamp":1794667276637,"version":"4.9.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.diabres.2025.112452","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T16:01:37Z","timestamp":1756915297000},"page":"112452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-3790","authenticated-orcid":false,"given":"Celestino","family":"Sardu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica Vittoria","family":"Marfella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando Carlo","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Nappo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ausilia","family":"Sellitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Carusone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"D\u2019Onofrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Consiglia","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Cioffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Volpicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine La","family":"Marca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natale","family":"Marrazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Landolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Abitabile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Marfella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Balestrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Marfella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.diabres.2025.112452_b0005","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J."},{"issue":"6","key":"10.1016\/j.diabres.2025.112452_b0010","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.hroo.2025.02.020","article-title":"Outcomes in diabetic vs nondiabetic patients requiring cardiac resynchronization therapy for heart failure: a meta-analysis","volume":"6","author":"Goyal","year":"2025","journal-title":"Heart Rhythm O2"},{"issue":"5","key":"10.1016\/j.diabres.2025.112452_b0015","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/ehf2.12876","article-title":"Differential effect of cardiac resynchronization therapy in patients with diabetes mellitus: a long-term retrospective cohort study","volume":"7","author":"Kahr","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"12","key":"10.1016\/j.diabres.2025.112452_b0020","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1161\/CIRCULATIONAHA.120.045888","article-title":"Glucagon-like peptide 1 receptor agonists and heart failure: the need for further evidence generation and practice guidelines optimization","volume":"142","author":"Khan","year":"2020","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.diabres.2025.112452_b0025","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.diabres.2025.112452_b0030","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12933-018-0778-9","volume":"17","author":"Sardu","year":"2018","journal-title":"Cardiovasc Diabetol."},{"issue":"4","key":"10.1016\/j.diabres.2025.112452_b0035","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1002\/ehf2.14784","article-title":"The effect of sodium-glucose co-transporter 2 inhibitors on outcomes after cardiac resynchronization therapy","volume":"11","author":"Bray","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.diabres.2025.112452_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107759","article-title":"Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator","volume":"216","author":"Sardu","year":"2025","journal-title":"Pharmacol Res"},{"issue":"10","key":"10.1016\/j.diabres.2025.112452_b0045","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.diabres.2025.112452_b0050","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12933-023-02118-6","article-title":"GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes","volume":"23","author":"Marfella","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 1","key":"10.1016\/j.diabres.2025.112452_b0055","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.2337\/dc23-S002","article-title":"2. Classification and diagnosis of diabetes: standards of care in diabetes-2023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"issue":"35","key":"10.1016\/j.diabres.2025.112452_b0060","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"ESC Scientific Document Group. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur Heart J."},{"issue":"15","key":"10.1016\/j.diabres.2025.112452_b0065","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"EMPEROR-reduced trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.diabres.2025.112452_b0070","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.diabres.2025.112452_b0075","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.diabres.2025.112452_b0080","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.diabres.2025.112452_b0085","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 receptor agonist therapy with andwithout SGLT2 inhibitors in patientswith type 2 diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.diabres.2025.112452_b0090","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400147","article-title":"Ertugliflozin to reduce arrhythmic burden in patients with ICDs\/CRT-Ds","volume":"3","author":"Benedikt","year":"2024","journal-title":"NEJM Evid."},{"issue":"Supplement_2","key":"10.1016\/j.diabres.2025.112452_b0095","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.336","article-title":"Impact of sodium-glucose cotransporter-2 (SLGT2) inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac devices Free","volume":"44","author":"Minguito Carazo","year":"2023","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.diabres.2025.112452_b0100","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s10840-025-02014-x","article-title":"Impact of SGLT2 inhibitor on clinical and echocardiographic outcomes in patients with CRT during long-term period","volume":"68","author":"Atabekov","year":"2025","journal-title":"J Interv Card Electrophysiol"},{"issue":"393","key":"10.1016\/j.diabres.2025.112452_b0105","article-title":"Impact of sacubitril\/valsartan and gliflozins on cardiac resynchronization therapy response in ischemic and non-ischemic heart failure patients","volume":"15","author":"Fonderico","year":"2023","journal-title":"Int J Cardiol"},{"issue":"17","key":"10.1016\/j.diabres.2025.112452_b0110","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.diabres.2025.112452_b0115","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"357","key":"10.1016\/j.diabres.2025.112452_b0120","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijcard.2022.03.032","article-title":"The effect of GLP-1 receptor agonists on N-terminal pro-brain natriuretic peptide. A scoping review and metanalysis","volume":"15","author":"Avogaro","year":"2022","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.diabres.2025.112452_b0125","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose cotransporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.diabres.2025.112452_b0130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2023.04.002","article-title":"The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: a meta-analysis of randomized controlled trials","volume":"114","author":"Fan","year":"2023","journal-title":"Eur J Intern Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725004668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725004668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:16:46Z","timestamp":1758777406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725004668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":26,"alternative-id":["S0168822725004668"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112452","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: A multicenter observational study","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112452"}}